Business Context and Reporting Period
Company: Rein Therapeutics, Inc. (RNTX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2025
Event: Entry into material definitive agreements with YA II PN, Ltd. ("Yorkville") to secure liquidity through a Pre-Paid Advance Agreement (PPA) and a Standby Equity Purchase Agreement (SEPA).
Key Financial Metrics and Agreements
Pre-Paid Advance Agreement (PPA)
- Total Capacity: Up to $6.0 million over 12 months.
- Initial Advance: $1.0 million face amount purchased on the Effective Date.
- Net Proceeds: $0.95 million (purchased at 95% of face value).
- Interest Rate: 8% annually, increasing to 18% upon default.
- Repayment Mechanism: Yorkville may require the Company to issue common stock to offset the balance. The purchase price is the lower of 115% of the prior day's VWAP or 95% of the lowest VWAP over the preceding seven days, subject to a floor price of $0.28 per share.
- Amortization Trigger: If the stock price falls below the floor for five of seven days, or other specific events occur, the Company must make monthly cash payments equal to the lesser of 25% of the initial advance or the outstanding principal.
Standby Equity Purchase Agreement (SEPA)
- Commitment Amount: Up to $15.0 million over 36 months.
- Company Option: The Company has the right, but not the obligation, to sell shares to Yorkville.
- Pricing: 96% of the lowest daily VWAP during the three trading days following a notice, subject to a minimum acceptable price set by the Company.
- Volume Limit: Sales are limited to 100% of the average daily trading volume over the five days prior to the request.
Costs and Fees
- PPA Fees: $25,000 paid for structuring and due diligence.
- SEPA Commitment Fee: $300,000 satisfied by the issuance of 213,099 shares of common stock ("Commitment Shares").
- SEPA Fees: $25,000 paid for structuring and due diligence.
Liquidity and Debt
The filing does not provide a clear value for the Company's total cash balance, total debt, or liquidity position outside of the specific proceeds from these new agreements. The agreements create a direct financial obligation (PPA) and a potential equity issuance obligation (SEPA).
Material Changes and Dilution Limits
- Exchange Cap: The total number of shares issuable under both the PPA and SEPA is limited to 19.9% of the outstanding common stock as of the Effective Date.
- Beneficial Ownership Limit: Yorkville and its affiliates cannot beneficially own more than 4.99% of the Company's outstanding common stock at any one time.
- Unregistered Sales: The 213,099 Commitment Shares were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933.
Guidance, Risks, and Contingencies
- Stock Price Risk: The PPA includes a "Floor Price" of $0.28. If the stock trades below this level for five of seven consecutive days, the Company must make mandatory cash payments, which could strain liquidity.
- Registration Risk: The Company must maintain an effective registration statement to issue shares under the PPA and SEPA. Failure to do so triggers mandatory cash payments under the PPA.
- Dilution Risk: Issuance of shares under these agreements will dilute existing shareholders, subject to the 19.9% exchange cap and 4.99% beneficial ownership limit.
- Interest Rate Risk: The PPA interest rate can jump from 8% to 18% upon an event of default.
Key Facts for Investor Verification
- Verify the Company's current cash balance and runway to assess the necessity of the $0.95 million immediate proceeds.
- Confirm the current trading price of RNTX relative to the $0.28 floor price to evaluate the risk of mandatory cash amortization payments.
- Review the Company's existing share count to calculate the potential dilution impact of the 19.9% exchange cap.
- Check the status of the Company's Form S-3 shelf registration statement to ensure it remains effective for future share issuances.
- Monitor the 4.99% beneficial ownership limit for Yorkville, which may restrict the Company's ability to access the full $15.0 million SEPA commitment if the stock price rises significantly.